Posted by Michael Wonder on 22 Aug 2019
AstraZeneca agrees to buy US FDA priority review voucher from Sobi
22 August 2019 - AstraZeneca today announced that it has agreed to buy a US FDA priority review voucher for a total cash consideration of $95 million from a subsidiary of Swedish Orphan Biovitrum (Sobi).
A priority review voucher entitles the holder to FDA priority review of a single new drug application or biologics license application, which reduces the target review time and may potentially lead to an expedited approval.
